

AmideBio



FOR IMMEDIATE RELEASE

Contact:

Misha Plam
AmideBio, LLC
President & CEO
m.plam@comcast.net
(303) 641-3669
<http://www.AmideBio.com>

Contact:

Lindsay Polak
Marketing/Communications Manager
University of Colorado Technology Transfer Office
Lindsay.polak@cu.edu
(303) 735-5518
<http://www.cu.edu/techtransfer>

AmideBio Licenses Peptide Manufacturing Technology from University of Colorado

Boulder, CO (PR Web) January 11, 2010 -- The University of Colorado and AmideBio, LLC have executed an exclusive license agreement allowing the Company to develop, manufacture and commercialize peptides based on the work of Michael Stowell, Ph.D., Associate Professor of Molecular, Cellular and Developmental Biology at the University of Colorado at Boulder.

The CU technology is a method for manufacturing recombinant proteins. These types of proteins are often key for treating diseases that cannot be addressed using conventional chemical therapeutics, but the field has historically been limited by challenges such as economical manufacturing and delivery. CU's technology circumvents these problems, particularly those associated with longer and more complex proteins, by leveraging a proprietary recombinant strategy that is economically viable and environmentally sustainable.

"We are pleased to be able to commercialize this technology developed at the University of Colorado, with which I have had an extensive and robust association," said Misha Plam, AmideBio President & CEO. "This advance in peptide manufacturing provides AmideBio with a real advantage in the market, by providing historically difficult to produce peptides, without compromising quality, yield or economics."

We are pleased to see the launch of this new life science venture based on technology developed in Dr. Stowell's lab," added Tom Smerdon, Director of Licensing and New Business Development at the CU Technology Transfer Office. "We believe this technology has strong commercial potential, and AmideBio has the business leadership necessary to make it a commercial reality."

About AmideBio, LLC

AmideBio based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPure™), economical and incorporate environmentally sustainable practices. For more information please visit <http://www.AmideBio.com>

About the Technology Transfer Office and the University of Colorado

The CU Technology Transfer Office (TTO) pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. The TTO provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit www.cu.edu/techtransfer.

AmideBio



The University of Colorado is a premier teaching and research university with four campuses: the University of Colorado at Boulder, the University of Colorado at Colorado Springs, the University of

Colorado Denver and the University of Colorado Anschutz Medical Campus. More than 55,000 undergraduate and graduate students are pursuing academic degrees on CU campuses. CU is ranked Seventh among public institutions in federal research expenditures in engineering and science by the National Science Foundation. Academic prestige is marked by the university's four Nobel laureates, seven MacArthur "genius" Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information, go to www.cu.edu.

###